PL4499039T3 - Stała kompozycja o przedłużonym uwalnianiu zawierająca antagonistów receptora bradykininy b2 - Google Patents

Stała kompozycja o przedłużonym uwalnianiu zawierająca antagonistów receptora bradykininy b2

Info

Publication number
PL4499039T3
PL4499039T3 PL23715488.5T PL23715488T PL4499039T3 PL 4499039 T3 PL4499039 T3 PL 4499039T3 PL 23715488 T PL23715488 T PL 23715488T PL 4499039 T3 PL4499039 T3 PL 4499039T3
Authority
PL
Poland
Prior art keywords
composition containing
receptor antagonists
release composition
containing bradykinin
solid prolonged
Prior art date
Application number
PL23715488.5T
Other languages
English (en)
Polish (pl)
Inventor
Christoph Gibson
Original Assignee
Pharvaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris Gmbh filed Critical Pharvaris Gmbh
Publication of PL4499039T3 publication Critical patent/PL4499039T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL23715488.5T 2022-03-25 2023-03-27 Stała kompozycja o przedłużonym uwalnianiu zawierająca antagonistów receptora bradykininy b2 PL4499039T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22164471 2022-03-25
PCT/EP2023/057792 WO2023180576A1 (en) 2022-03-25 2023-03-27 Solid extended-release composition comprising bradykinin b2-receptor antagonists

Publications (1)

Publication Number Publication Date
PL4499039T3 true PL4499039T3 (pl) 2026-03-30

Family

ID=80952430

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23715488.5T PL4499039T3 (pl) 2022-03-25 2023-03-27 Stała kompozycja o przedłużonym uwalnianiu zawierająca antagonistów receptora bradykininy b2

Country Status (24)

Country Link
US (1) US20250228782A1 (enExample)
EP (2) EP4499039B1 (enExample)
JP (1) JP2025510860A (enExample)
KR (1) KR20240161195A (enExample)
CN (1) CN119136786A (enExample)
AU (1) AU2023240388A1 (enExample)
CA (1) CA3250834A1 (enExample)
CO (1) CO2024012885A2 (enExample)
DK (1) DK4499039T3 (enExample)
ES (1) ES3062435T3 (enExample)
FI (1) FI4499039T3 (enExample)
HR (1) HRP20260203T1 (enExample)
IL (1) IL315700A (enExample)
LT (1) LT4499039T (enExample)
MA (1) MA69210B1 (enExample)
MX (1) MX2024011704A (enExample)
PL (1) PL4499039T3 (enExample)
PT (1) PT4499039T (enExample)
RS (1) RS67776B1 (enExample)
SI (1) SI4499039T1 (enExample)
SM (1) SMT202600057T1 (enExample)
TW (1) TW202345810A (enExample)
WO (1) WO2023180576A1 (enExample)
ZA (1) ZA202408059B (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168667A (zh) 1994-10-27 1997-12-24 藤沢药品工业株式会社 用作缓激肽拮抗剂的吡啶并嘧啶酮,喹啉和稠合的n-杂环化合物
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
EP1085895A1 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Bradykinin antagonists
EP1123288A1 (en) 1998-10-21 2001-08-16 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
JP2005525398A (ja) 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. B2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) * 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
AR118983A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
CA3198246A1 (en) * 2020-11-12 2022-05-19 Pharvaris Gmbh Prophylaxis and treatment of angioedema

Also Published As

Publication number Publication date
US20250228782A1 (en) 2025-07-17
SI4499039T1 (sl) 2026-04-30
IL315700A (en) 2024-11-01
LT4499039T (lt) 2026-02-25
ES3062435T3 (en) 2026-04-10
AU2023240388A1 (en) 2024-11-07
PT4499039T (pt) 2026-02-17
MA69210B1 (fr) 2026-02-27
CO2024012885A2 (es) 2024-10-10
TW202345810A (zh) 2023-12-01
FI4499039T3 (fi) 2026-02-05
MX2024011704A (es) 2024-11-08
JP2025510860A (ja) 2025-04-15
EP4499039B1 (en) 2025-12-03
CN119136786A (zh) 2024-12-13
ZA202408059B (en) 2026-01-28
SMT202600057T1 (it) 2026-03-09
HRP20260203T1 (hr) 2026-03-27
EP4499039A1 (en) 2025-02-05
DK4499039T3 (da) 2026-02-16
EP4684830A2 (en) 2026-01-28
CA3250834A1 (en) 2023-09-28
KR20240161195A (ko) 2024-11-12
WO2023180576A1 (en) 2023-09-28
EP4684830A3 (en) 2026-04-01
RS67776B1 (sr) 2026-03-31

Similar Documents

Publication Publication Date Title
PL2340828T3 (pl) Kombinacje farmaceutyczne antagonisty receptora angiotensyny i inhibitora nep
EP4221690A4 (en) PHARMACEUTICAL COMPOSITIONS
EP4041770A4 (en) MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS
EP4135699A4 (en) Pharmaceutical compositions
EP4352194C0 (en) COMPOSITION OF TABLET
EP4265609A4 (en) SELECTIVE THYROID HORMONE RECEPTOR BETA AGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE
EP4257597A4 (en) LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
EP4323007A4 (en) Polypeptide formulations
EP4511368A4 (en) Ccr4 antagonists
EP3795166A4 (en) PHARMACEUTICAL COMPOSITION OF KOR RECEPTOR AGONIST
DK3819007T3 (da) Doseringsplan for anti-bcma-midler
EP4452969A4 (en) INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS
HRP20260166T1 (hr) Čvrsti sastav koji sadrži solubilizirane antagoniste bradikinin b2 receptora
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
EP4271359C0 (en) ORODISPPERABLE POWDER COMPOSITION
EP4179105A4 (en) COMPOSITIONS COMPRISING ANTIBODIES DIRECTED AGAINST HUMAN IDO-2
EP3908284A4 (en) NEW FORMULATIONS WITH LEUKOTRIEN RECEPTOR ANTAGONISTS
DK3969126T3 (da) Deodorantsammensætning
DK4499039T3 (da) Faststofretardsammensætning omfattende bradykinin b2-receptorantagonister
EP4361146A4 (en) Compound, endothelin-a receptor antagonist and pharmaceutical composition
EP4479041A4 (en) MULTIMERIZATION PHARMACEUTICAL COMPOSITIONS
EP4349366A4 (en) PHARMACEUTICAL COMPOSITION
DK4203919T3 (da) Lipidbaseret sammensætning til oral administration af bradykinin-b2-receptorantagonister
EP4268830A4 (en) PHARMACEUTICAL COMPOSITION
EP4265253A4 (en) PHARMACEUTICAL COMPOSITION